{"id":"NCT02338960","sponsor":"Palatin Technologies, Inc","briefTitle":"2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","officialTitle":"Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2016-08","completion":"2017-06-29","firstPosted":"2015-01-15","resultsPosted":"2021-01-28","lastUpdate":"2021-01-28"},"enrollment":714,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypoactive Sexual Desire Disorder"],"interventions":[{"type":"DRUG","name":"Bremelanotide","otherNames":["BMT","PT-141"]},{"type":"DRUG","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bremelanotide (BMT/BMT)","type":"EXPERIMENTAL"},{"label":"Placebo (PBO/BMT)","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.","primaryOutcome":{"measure":"Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.","timeFrame":"8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)","effectByArm":[{"arm":"Bremelanotide BMT/BMT","deltaMin":0.63,"sd":1.036},{"arm":"Placebo PBO/BMT","deltaMin":0.21,"sd":0.922}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":91,"countries":["United States","Canada"]},"refs":{"pmids":["10782451","36809187","35147466","33538638","33033885","31599847","31599840","28189361"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":303},"commonTop":["Nausea","Flushing","Sunburn","Headache","Injection site pain"]}}